Cephalon touts new pain study data

Cephalon announced that a Phase III trial of Fentora demonstrated a statistically significant response for lower back pain. Fentora is approved as a therapy for cancer pain. In the trial, Fentora provided significant relief within 10 minutes compared to a placebo. Fentora is an oral therapy absorbed through the lining of the cheek. Cephalon shares were buoyed by the announcement.

- Here's the AP report on Fentora